Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
hypnotic orexin receptor antagonist |
| gptkbp:approvedBy |
gptkb:FDA
2014 |
| gptkbp:ATCCode |
N05CM17
|
| gptkbp:brand |
gptkb:Belsomra
|
| gptkbp:CASNumber |
1030377-33-3
|
| gptkbp:developedBy |
gptkb:Merck_&_Co.
|
| gptkbp:eliminationHalfLife |
12 hours
|
| gptkbp:excretion |
urine
feces |
| gptkbp:hasMolecularFormula |
C23H23ClN6O2
|
| https://www.w3.org/2000/01/rdf-schema#label |
suvorexant
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
orexin receptor antagonist
|
| gptkbp:metabolism |
liver (CYP3A, minor CYP2C19)
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:proteinBinding |
99%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
fatigue
headache dry mouth somnolence abnormal dreams |
| gptkbp:usedFor |
insomnia
|
| gptkbp:bfsParent |
gptkb:Belsomra
|
| gptkbp:bfsLayer |
6
|